CANLI
Yükleniyor Veriler getiriliyor…
SCI-Expanded JCR Q1 Özgün Makale Scopus
Liraglutide as a novel therapeutic for overweight in canines: A clinical study
The Veterinary Journal 2025 Cilt 313
Scopus Eşleşmesi Bulundu
313
Cilt
Scopus Yazarları: Oğuzhan Kahraman, Metin Celik, T. M. Parlak, S. Damar, Burak Dik, Durmus Hatipoglu, Zekeriya Safa İnanç
Özet
Background: The overweight/obesity in dogs is defined as a condition of abnormal fat accumulation or, beyond that, a multifactorial condition involving excessive fat accumulation along with different factors (insufficient physical activity, genetics (breed), metabolism, the microbiome, etc.). Preclinical obesity conditions increases the risk of progressing to clinical obesity and developing obesity-associated diseases such as type 2 diabetes, cardiovascular disease, certain cancers, and mental disorders. Objectives: This study aimed to determine the weight-loss effects of liraglutide in dogs that do not engage in sufficient exercise, are fed table scraps, and develop obesity owing to aging. Animals: In this study, 21 senior Golden Retriever dogs were divided into three equal groups. Methods: Group 1 was considered healthy and consisted of dogs within the range of ideal body live weight and body condition scores, and fed dry commercial dog food at the amount of their daily metabolizable energy requirements. Group 2 included seven senior dogs with obesity fed commercial dry food adjusted for their daily metabolizable energy requirements. Group 3 comprised seven senior dogs with obesity fed commercial dry food adjusted for their daily energy requirements and concurrently treated with subcutaneous liraglutide at a dose of 1.2 mg/dog. The trial lasted for 40 days. Results: Liraglutide treatment resulted in a decrease in body condition score (BCS) and body weight by day 40, although the reduction in body weight (13.27 %) did not reach statistical significance. Liraglutide significantly lowered cholesterol and triglyceride levels, and appetite tests revealed a marked suppression of food intake over consecutive days in treated dogs. Conclusions and clinical importance: Liraglutide treatment may offer a viable option for treating obesity in dogs, and could potentially be used as a new anti-obesity drug in canines. Future long-term and detailed trials of liraglutide in dogs with obesity could facilitate its effective use in the field.
Anahtar Kelimeler (Scopus)
Liraglutid GLP-1 Overweight Canine

Anahtar Kelimeler

Veteriner Fizyoloji Liraglutid GLP-1 Overweight Canine
mavi = YÖKSİS   yeşil = Scopus

Makale Bilgileri

Dergi The Veterinary Journal
ISSN 1090-0233
Yıl 2025 / 9. ay
Cilt / Sayı 313
Makale Türü Özgün Makale
Hakemlik Hakemli
Endeks SCI-Expanded
JCR Quartile Q1
TEŞV Puanı 3,00
Yayın Dili İngilizce
Kapsam Uluslararası
Toplam Yazar 6 kişi
Erişim Türü Basılı+Elektronik
Erişim Linki Makaleye Git
Alan Sağlık Bilimleri Temel Alanı Veteriner Fizyolojisi Veteriner Fizyoloji

YÖKSİS Yazar Kaydı

Yazar Adı DİK BURAK,HATİPOĞLU DURMUŞ,KAHRAMAN OĞUZHAN,PARLAK TUĞBA MELİKE,İNANÇ ZEKERİYA SAFA,Damar Samed
YÖKSİS ID 8900345

Metrikler

JCR Quartile Q1
TEŞV Puanı 3,00
Yazar Sayısı 6